Centaur other research news

The Sunnyvale, Calif., company received a $100,000 Phase I SBIR from the National Institute of Neurological Disorders and Stroke to develop drugs to treat ALS using Centaur's NRT antioxidant technology.

According to Centaur, research suggests that oxygen free radicals and oxidative damage are improtant in the progression of the disease. ...